Medicare’s rules for covering prescription drugs like Ozempic and Zepbound are complex in 2026. These drugs belong to a class called GLP‑1 receptor agonists, often used to treat type 2 diabetes, reduce cardiovascular risk, or help manage weight.
Historically Medicare did not cover weight‑loss medications, including many newer GLP‑1 drugs, due to federal law.
However, new programs coming in 2026 may expand access for some beneficiaries beyond traditional coverage.
GLP‑1 drug and why does Medicare care
GLP‑1 drugs are prescription medicines that act like the glucagon‑like peptide‑1 hormone. They help control blood sugar and reduce appetite. Brand names include Ozempic (semaglutide) and Zepbound (tirzepatide).
Calculate Your 2026 COLA Increase →Some GLP‑1 drugs are approved by the U.S. Food and Drug Administration (FDA) for type 2 diabetes, others for weight management, and some for additional conditions like cardiovascular risk reduction.
Medicare coverage depends on the FDA‐approved use of the drug and existing law. Under standard rules, Medicare Part D (prescription drug benefit) and Medicare Advantage plans with drug coverage generally cover drugs when they are medically necessary to treat a covered condition such as diabetes, but they do not cover medications solely for weight loss.
Does Medicare cover Ozempic in 2026?
As of 2026, Medicare may cover Ozempic when it is prescribed for an FDA‑approved condition such as type 2 diabetes or in some cases to reduce cardiovascular risk, but not for weight loss alone.
Federal law currently prohibits Medicare Part D from covering drugs prescribed solely for weight loss.
If your doctor prescribes Ozempic for diabetes and your Part D or Medicare Advantage drug plan includes the drug on its formulary (list of covered drugs), Medicare may cover it with the usual copays and deductibles.
If you use Ozempic off‑label or for weight management alone, Part D plans generally will not cover the cost. Always check your specific plan’s formulary and prior authorization requirements.
Does Medicare cover Zepbound in 2026?
Medicare generally does not cover Zepbound for weight loss under Part D because federal law excludes medications prescribed solely for weight reduction from coverage. However, Medicare Part D plans may cover Zepbound if it is prescribed and FDA‑approved for another medical condition, such as obstructive sleep apnea (OSA) in people with obesity.
Coverage for this indication depends on whether your specific Part D or Medicare Advantage plan includes it on the formulary and approves the prescription under medical necessity rules.
Residing in 2026, not all plans list Zepbound on their formularies even for OSA. Many beneficiaries need a prior authorization or medical documentation to show that it is medically necessary for a covered condition beyond weight loss.
Check with your specific plan and doctor to confirm coverage options and requirements.
What changes are coming in 2026 that affect GLP‑1 coverage?
A new demonstration program called the Medicare GLP‑1 Bridge will begin July 1, 2026 and run through the end of the year.
This program is a short‑term federal demonstration to provide early access to certain GLP‑1 drugs, including Wegovy and Zepbound, when used to reduce excess body weight and maintain weight reduction in combination with lifestyle changes. It operates outside of the usual Medicare Part D benefit structure.
Under this bridge program, eligible Medicare beneficiaries enrolled in a Medicare Part D prescription drug plan or Medicare Advantage plan with drug coverage and meeting prior authorization criteria can access selected GLP‑1 drugs with a standard $50 monthly copay.
This payment structure is set by Medicare and does not count toward most Part D out‑of‑pocket costs. Benefits are administered through a central processor rather than individual Part D plan sponsors.
To qualify for the Medicare GLP‑1 Bridge, a medical provider must document your clinical need, including body mass index (BMI) thresholds (for example BMI ≥ 35 or BMI ≥ 30 with certain comorbidities) and evidence of structured nutrition and physical activity.
Additional detailed criteria will be released by CMS in 2026.
Will Medicare cover GLP‑1 drugs for weight loss long term?
The Medicare GLP‑1 Bridge is a temporary program. It is designed to operate from July to December 2026 and serve as an early step toward a larger initiative called the BALANCE Model, which is scheduled to begin January 1, 2027 with broader access pathways in Medicare Part D.
Beneficiaries who participate in the bridge program will need to enroll in a Part D plan that opts into the BALANCE Model in 2027 for continued access.
Unless Congress changes the law, Medicare still cannot routinely cover drugs prescribed exclusively for weight loss outside these pilot or demonstration models.
Standard Medicare drug plans will continue to require an FDA‑approved covered indication for reimbursement.
How do Medicare Part D and Medicare Advantage plans affect coverage?
Medicare Part D and Medicare Advantage (MA‑PD) plans set their own formularies and may require prior authorization or step therapy before covering a GLP‑1 drug for a covered indication.
Even if a drug like Ozempic or Zepbound is FDA‑approved for a non‑weight‑loss use, it may not appear on every plan’s formulary. If it doesn’t appear, you can ask your doctor to request a formulary exception from the plan to seek coverage.
Each Part D or MA‑PD plan has its own cost sharing, deductible, and coverage rules. Beneficiaries should review plan materials during enrollment periods or contact the plan to understand coverage, costs, and prior authorization requirements for specific GLP‑1 drugs.
Are there current legal barriers to coverage?
Yes. Federal law, specifically the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, prohibits Medicare Part D from covering drugs when they are used for weight loss or weight management alone.
That means even if a GLP‑1 drug is FDA‑approved for weight loss, Medicare generally cannot pay for it unless it is being used to treat another covered medical condition.
